Bacterial and fungal co-infection is a major barrier in COVID-19 patients: A specific management and therapeutic strategy is required.
World J Virol
; 11(2): 107-110, 2022 Mar 25.
Article
in English
| MEDLINE | ID: covidwho-1791988
ABSTRACT
Microbial co-infections are another primary concern in patients with coronavirus disease 2019 (COVID-19), yet it is an untouched area among researchers. Preliminary data and systematic reviews only show the type of pathogens responsible for that, but its pathophysiology is still unknown. Studies show that these microbial co-infections are hospital-acquired/nosocomial infections, and patients admitted to intensive care units with invasive mechanical ventilation are highly susceptible to it. Patients with COVID-19 had elevated inflammatory cytokines and a weakened cell-mediated immune response, with lower CD4+ T and CD8+ T cell counts, indicating vulnerability to various co-infections. Despite this, there are only a few studies that recommend the management of co-infections.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Reviews
/
Systematic review/Meta Analysis
Language:
English
Journal:
World J Virol
Year:
2022
Document Type:
Article
Affiliation country:
Wjv.v11.i2.107
Similar
MEDLINE
...
LILACS
LIS